Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270652 | 0.79 | TAAR1 (0.42) | TAAR1HTR2ADPP4TSHRF2 | |
| SCHEMBL1645203 | 0.75 | TSHR (0.42) | TAAR1HTR2ADPP4TSHRF2 | |
| SCHEMBL9339406 | 0.75 | TAAR1 (0.50) | TAAR1HTR2ADPP4TSHRF2 | |
| SCHEMBL7935090 | 0.75 | LMNA (0.39) | TAAR1HTR2ADPP4TSHRF2 | |
| SCHEMBL14954674 | 0.75 | CYP2C19 (0.41) | TAAR1HTR2ATSHRHRH1MTOR | |
| SCHEMBL3454935 | 0.71 | TRPA1 (0.38) | TAAR1HTR2AHRH1MTORRAB9A | |
| SCHEMBL10768536 | 0.70 | DPP4 (0.41) | TAAR1HTR2ADPP4TSHRF2 | |
| SCHEMBL8470916 | 0.70 | SRC (0.43) | LMNAL3MBTL1CYP2D6 | |
| SCHEMBL4774509 | 0.69 | DPP4 (0.45) | TAAR1HTR2ADPP4TSHRF2 | |
| SCHEMBL4194601 | 0.69 | HDAC3 (0.35) | TAAR1HTR2ADPP4HRH1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110678447-B | Modified nucleic acid monomer compounds and oligonucleotide analogues | 卫材R&D管理有限公司 | 2023-12-12 | — | — | CN | claimed |
| EP-3643706-B1 | MODIFIED NUCLEIC ACID MONOMERS AND OLIGONUCLEIC ACID ANALOGUES, WITH HIGH BIOLOGICAL STABILITY AND TARGET GENE SILENCING ACTIVITY, FOR USE IN THERAPY AND DIAGNOSIS OF CANCER AND VIRAL DISEASES | EISAI R&D MAN CO LTD (JP) | 2023-11-15 | — | — | EP | claimed |
| US-9896473-B2 | Thiol compounds and the use thereof for the synthesis of modified oligonucleotides | ETABLISSEMENT FRANCAIS DU SANG (FR) | 2018-02-20 | — | — | US | claimed |
| EP-2834253-B1 | THIOL COMPOUNDS AND THE USE THEREOF FOR THE SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-03-29 | — | — | EP | claimed |
| US-20150158964-A1 | THIOL COMPOUNDS AND THE USE THEREOF FOR THE SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2015-06-11 | — | — | US | claimed |
| EP-0948514-B1 | METHOD FOR THE SYNTHESIS OF NUCLEOTIDE OR OLIGONUCLEOTIDE PHOSPHORAMIDITES | ISIS PHARMACEUTICALS INC (US) | 2005-04-27 | — | — | EP | claimed |
| EP-0948512-B1 | METHOD OF SYNTHESIZING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2004-10-06 | — | — | EP | claimed |
| US-6780989-B2 | HYBRID OLIGONUCLEOTIDE | ISIS PHARMACEUTICALS, INC. | 2004-08-24 | — | — | US | claimed |
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | CHATTOPADHYAYA JYOTI (SE) | 2004-07-22 | — | — | US | claimed |
| EP-1332150-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | Chattopadhyaya, Jyoti (SE) | 2003-08-06 | — | — | EP | claimed |
| US-6172217-B1 | SULFURIZATION OF PHOSPORDIAMIDITE; DEBLOCKING | ISIS PHARMACEUTICALS INC. | 2001-01-09 | — | — | US | claimed |
| US-6103891-A | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-15 | — | — | US | claimed |
| EP-0948512-A1 | METHOD OF SYNTHESIZING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-10-13 | — | — | EP | claimed |
| EP-0948514-A1 | METHOD FOR THE SYNTHESIS OF NUCLEOTIDE OR OLIGONUCLEOTIDE PHOSPHORAMIDITES | ISIS PHARMACEUTICALS, INC. (US) | 1999-10-13 | — | — | EP | claimed |
| US-5955600-A | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1998029429-A1 | METHOD FOR THE SYNTHESIS OF NUCLEOTIDE OR OLIGONUCLEOTIDE PHOSPHORAMIDITES | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | claimed |
| WO-1998029427-A1 | METHOD OF SYNTHESIZING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | claimed |
| US-5721350-A | Deuterated nucleosides | CHATTOPADHYAYA JYOTI (SE) | 1998-02-24 | — | — | US | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | RNASEH1, RNASEL, NSUN2 | TAAR1 3762/4885HTR2A 1755/4885DPP4 1649/4885 |
| US-20150158964-A1 | THIOL COMPOUNDS AND THE USE THEREOF FOR THE SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | TST, APEX1, TMT1A | TAAR1 1297/4885HTR2A 4701/4885DPP4 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.